1 October 2021
SERAPHIM SPACE INVESTMENT TRUST PLC
(the "Company")
TOTAL VOTING RIGHTS
In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, as at 30 September 2021, the Compa ny had 212,129,854 Ordinary Shares in issue, each with equal voting rights. No shares are held in treasury. Therefore, the total number of voting rights in the Company is 212,129,854.
Shareholders should use 212,129,854 as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Seraphim Space (Manager) LLP (via SEC Newgate)
Mark Boggett, CEO / James Bruegger, CIO / Rob Desborough
SEC Newgate (Communications advisers)
seraphim@secnewgate.co.uk
Emma Kane / Clotilde Gros / Bob Huxford +44 (0) 3757 6767
Deutsche Bank
Mark Hankinson / Neil Collingridge / Neil Coleman +44 (0) 20 754 58000
J.P. Morgan Cazenove
William Simmonds / Jérémie Birnbaum / Rupert Budge +44 (0) 20 7742 4000
Ocorian Administration (UK) Limited seraphimteam@ocorian.com
Eimear Coleman / Peter Davidson +44 28 9078 5880
Notes to Editors:
About Seraphim Space Investment Trust
Seraphim Space Investment Trust is the world's first listed fund focused on Space Tech. The Company seeks exposure predominantly to early and growth stage private financed Space Tech businesses that have the potential to dominate globally and that are sector leaders with first mover advantages in areas such as climate, communications, mobility and cyber security.
The Company listed on the Premium Segment of the London Stock Exchange on 14 July 2021, following an oversubscribed IPO raising £178.4 million. It currently has exposure to 15 Tech Space companies and has agreed to acquire investments in a further four companies by 31 December 2021 with a current estimated aggregate value of £70 million (subject to variation ahead of the acquisitions being completed) and issue shares with a corresponding value (at the IPO price) to the selling investors.
Further information is available at: www.seraphim.vc